• Home
  • About Us
    • About Us
    • Leadership Team
  • Science
    • Biologics
    • Biomanufacturing
    • Pipeline
  • Investors
    • Overview
    • SEC Filings
    • Press Releases
    • Presentations
    • Corporate Governance
    • Investor Resources
      semaglutide
      • Email Alerts
      • FAQs
      • Tax Documents
  • Careers
  • Contact Us

Tivic Health Survey Reveals Allergy Season Impacts Job Performance, Commuting, and Ability to Enjoy Outdoor Activities

May 25, 2022 | Press Releases

SAN FRANCISCO, May 25, 2022 — Tivic Health® Systems, Inc. (Nasdaq: TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced survey findings revealing that seasonal allergies impact job...

Tivic Health Reports First Quarter 2022 Financial Results

May 16, 2022 | Press Releases

77% year-over-year growth in unit sales direct-to-consumer; 219% increase in gross profit. SAN FRANCISCO – Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a commercial-phase health technology company that develops and commercializes...

Tivic Health Reports First Quarter 2022 Financial Results

May 16, 2022 | Press Releases

77% year-over-year growth in unit sales direct-to-consumer; 219% increase in gross profit. SAN FRANCISCO – Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a commercial-phase health technology company that develops and commercializes...

Tivic Health CEO Jennifer Ernst to Speak at Fortune Brainstorm Health

May 9, 2022 | Press Releases

SAN FRANCISCO – Jennifer Ernst, CEO of Tivic Health® Systems, Inc. (Nasdaq: TIVC), is an invited speaker at FORTUNE Brainstorm Health and will participate on the panel Driving Digital Health: Where Wearables Are Headed Next. The session will take place on...

Tivic Health to Report First Quarter 2022 Earnings on May 16th Via Conference Call and Webcast

May 4, 2022 | Press Releases

SAN FRANCISCO – Tivic Health® Systems, Inc. (Nasdaq: TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced that it will report financial results for the first quarter of 2022 via...
« Older Entries
Next Entries »

Recent Posts

  • Valion Bio Welcomes Former U.S. Army Regulatory Leader and Biotech CEO Dr. Armand Balboni as Advisor in Run-up to Entolimod Therapeutic Efficacy Data Readout
  • Valion Bio Reports Completion of 200-Liter Entolimod Production Run; Material Supplying Ongoing AFRRI Study
  • Valion Bio Reinforces Commitment to American Troops; Discusses Entolimod with Attendees at RW Baird’s National Security Conference
  • Valion Bio Advancing Entolimod into U.S. Government-Funded Therapeutic Efficacy Study Following Positive Safety Results
  • Valion Bio Announces Positive Safety Results From U.S. Government-Funded Entolimod Study, Paving Way For Therapeutic Efficacy Evaluation

Recent Comments

No comments to show.
©2026 Valion Bio

Privacy Policy

For ClearUP customer questions regarding warranty or other device inquiries, please reach out to customerservice@tivichealth.com.